{"Clinical Trial ID": "NCT02115984", "Intervention": ["INTERVENTION 1:", "- Chemotherapy & Panagen", "The chemotherapy course consists of 500 mg/m2 cyclophosphate, 50 mg/m2 doxorubicin and 500 mg/m2 fluorouracil administered intravenously in one day.", "Panagen 5 mg tablets orally every 2-3 h (six times a day) for 18 days. Patients start receiving the preparation immediately after chemotherapy and take three tablets for 6 h, i.e. one tablet every 2 h. Then, patients stop taking the preparation and resume administration after 42 h, i.e. 48 h after chemotherapy (Day 3) and continue administration for 17 days (Day 20 after chemotherapy).", "INTERVENTION 2:", "- Chemotherapy & Placebo", "The chemotherapy course consists of 500 mg/m2 cyclophosphate, 50 mg/m2 doxorubicin and 500 mg/m2 fluorouracil administered intravenously in one day.", "Patients start receiving placebo tablets immediately after chemotherapy and take three tablets for 6 h, i.e. one tablet every 2 h. Then patients stop taking the preparation and resume administration after 42 h, i.e. 48 h after chemotherapy (day 3) and continue administration for 17 days (day 20 after chemotherapy)."], "Eligibility": ["Incorporation criteria:", "Signed and dated informed written consent", "Women 18 years of age", "Stage II-IV breast cancer (with distant metastases)", "Patients will undergo chemotherapy with cyclophosphane/doxorubicin/fluorouracil as standard chemotherapy for the treatment of breast cancer.", "Patients have not previously undergone chemotherapy.", "\u2022 Functional status according to the Eastern Cooperative Oncology Group (ECOG) 2", "Number of leukocytes of 3 \u00d7 109/L prior to treatment", "Number of neutrophils of 1.5 \u00d7 109/L prior to treatment", "Number of platelets 100 \u00d7 109/L prior to treatment", "Adequate cardiac function", "adequate hepatic function, i.e. alanine aminotransferase/aspartate aminotransferase (ALT/ASAT) activity < 2.5 \u00d7 upper limit of normal (ULN); acid phosphatase activity < 5 \u00d7 ULN; and bilirubin concentration < 5 \u00d7 ULN; and", "adequate renal function, i.e. creatinine concentration in blood serum < 1.5 \u00d7 ULN; urea concentration < ULN; and endogenous clearance of creatinine", "- Exclusion criteria:", "\u2022 Participation in clinical trials less than 30 days prior to sequential randomization", "A prior exposure to Panagen or any other leucostimulatory medicinal product at a stage of clinical development", "Hypersensitivity to cyclophosphane, doxorubicin or fluoruracil", "\u25cf Therapy with systemic active antibiotics less than 72 h prior to the start of chemotherapy", "\u2022 Long-term oral use of corticosteroids", "Prior radiation therapy was performed less than 4 weeks prior to randomization.", "A Previous Transplantation of Hematopoietic Stem Cells", "Other malignant neoplasms in the last 5 years, except basal or flat cell carcinomas or intraepithelial cervix carcinomas", "Any disease or condition that, in the opinion of the researcher, may affect the patient's safety or the estimation of a final test point; and", "Pregnant and lactating women; fertile patients should use chemical contraceptives or barrier contraceptives during the trial period"], "Results": ["Performance measures:", "The amount of leukocytes and neutrophils in patients' blood", "[Unspecified]", "Delay: Baseline, 21st day after 2nd chemotherapy (day 42 after basic chemotherapy), 21st day after 3rd chemotherapy (day 63 after basic chemotherapy)", "Results 1:", "Title of the arm/group: Chemotherapy & Panagen", "Description of the arm/group: Chemotherapy: The chemotherapy course consists of 500 mg/m2 cyclophosphate, 50 mg/m2 doxorubicin and 500 mg/m2 fluorouracil administered intravenously in one day.", "Panagen 5 mg tablets orally every 2-3 h (six times a day) for 18 days. Patients start receiving the preparation immediately after chemotherapy and take three tablets for 6 h, i.e. one tablet every 2 h. Then, patients stop taking the preparation and resume administration after 42 h, i.e. 48 h after chemotherapy (Day 3) and continue administration for 17 days (Day 20 after chemotherapy).", "Total number of participants analysed: 51", "Median (interquartile range)", "Unit of measurement: 10^9 leukocyte base cells/L: 8.1 (6.5 to 8.8)", "\u2022 Leukocytes after 2nd chemotherapy: 6.6 (5.9 to 7.2)", "\u2022 Leukocytes after 3rd chemotherapy: 5 (4.6 to 5.5)", "To the inclusion of neutrophils: 5.33 (4.42 to 6.36)", "Neutrophils after 2nd chemotherapy: 4.62 (3.43 to 4.82)", "- Neutrophils after 3rd chemotherapy: 3.19 (1.81 to 3.58)", "Results 2:", "Title of the arm/group: Chemotherapy & Placebo", "Description of the arm/group: Chemotherapy: The chemotherapy course consists of 500 mg/m2 cyclophosphate, 50 mg/m2 doxorubicin and 500 mg/m2 fluorouracil administered intravenously in one day.", "Patients start receiving placebo tablets immediately after chemotherapy and take three tablets for 6 h, i.e. one tablet every 2 h. Then patients stop taking the preparation and resume administration after 42 h, i.e. 48 h after chemotherapy (day 3) and continue administration for 17 days (day 20 after chemotherapy).", "Total number of participants analysed: 16", "Median (interquartile range)", "Unit of measurement: 10^9 leukocyte base cells/L: 7.2 (6.5 to 7.9)", "\u2022 Leukocytes after 2nd chemotherapy: 4.8 (4.1 to 5.6)", "\u2022 Leukocytes after 3rd chemotherapy: 4.1 (3.8 to 4.4)", "To the inclusion of neutrophils: 5.2 (4.2 to 6.55)", "\u25cf Neutrophils after 2nd chemotherapy: 2.76 (2.22-3.27)", "\u25cf Neutrophils after 3rd chemotherapy: 2.44 (2.31 to 2.63)"], "Adverse Events": ["Undesirable Events 1:", "Total: 57/57 (100.00 per cent)", "- Dry eyes 13/33 (39.39 %)", "Stomach burns 9/33 (27.27%)", "- Nausea after TB (before 7th day) 57/57 (10.0%)", "- Herpes rash 0/33 (0.00 %)", "- Dry skin 15/33 (45.45 per cent)", "Alopecia 57/57 (100.00 per cent)", "Adverse Events 2:", "Total: 23/23 (100.00 per cent)", "- Dry eyes 2/11 (18.18 per cent)", "- Stomach burns 2/11 (18.18 per cent)", "\u2022 Nausea after TB (before 7th day) 23/23 (100.00 %)", "3/11 (27.27 per cent)", "9/11 (81.8%) dry skin", "Alopecia 23/23 (100.00 per cent)"]}